Search results for "Tamoxifen"

showing 10 items of 70 documents

Estrogen receptor (ER)-mediated transcriptional regulation of the human corticotropin-releasing hormone-binding protein promoter: differential effect…

2004

CRH-binding protein (CRH-BP) regulates activation of the hypothalamic-pituitary-adrenal (HPA) axis by binding and inhibiting CRH. We investigated for the first time transcriptional regulation of the human CRH-BP promoter using transient transfections. Estrogen receptors (ERs) contributed to ligand-independent constitutive activation of the promoter, whereas in the presence of estradiol ERalpha induced and ERbeta repressed promoter activity in a dose-dependent manner. TNFalpha inhibited promoter induction by ERalpha in the absence and presence of estradiol. Three ERE half-sites in the CRH-BP promoter bound ERalpha and ERbeta in an EMSA, and disruption of ERE half-sites by site-directed mutag…

Transcriptional Activationendocrine systemTranscription Geneticmedicine.drug_classResponse elementEstrogen receptorBiologyResponse ElementsEndocrinologymedicineTranscriptional regulationTumor Cells CulturedAnimalsEstrogen Receptor betaHumansPromoter Regions GeneticMolecular BiologyPsychological repressionConserved SequenceEstradiolNeurosecretionTumor Necrosis Factor-alphaEstrogen AntagonistsEstrogen Receptor alphaGeneral MedicineTransfectionMolecular biologyTamoxifenEstrogenPituitary GlandMutationTumor necrosis factor alphaCarrier Proteinshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugMolecular endocrinology (Baltimore, Md.)
researchProduct

Release of dendritic cells from cognate CD4 + T-cell recognition results in impaired peripheral tolerance and fatal cytotoxic T-cell mediated autoimm…

2012

Resting dendritic cells (DCs) induce tolerance of peripheral T cells that have escaped thymic negative selection and thus contribute significantly to protection against autoimmunity. We recently showed that CD4 + Foxp3 + regulatory T cells (Tregs) are important for maintaining the steady-state phenotype of DCs and their tolerizing capacity in vivo. We now provide evidence that DC activation in the absence of Tregs is a direct consequence of missing DC–Treg interactions rather than being secondary to generalized autoimmunity in Treg-less mice. We show that DCs that lack MHC class II and thus cannot make cognate interactions with CD4 + T cells are completely unable to induce peripheral CD8 +…

TransgeneGenes MHC Class IIAutoimmunityMice Transgenicchemical and pharmacologic phenomenaAdaptive ImmunityLymphocyte Activationmedicine.disease_causeT-Lymphocytes RegulatoryAutoimmunityMicemedicineAnimalsCytotoxic T cellHomeodomain ProteinsMHC class IIMultidisciplinarybiologyPeripheral ToleranceBody WeightHistological TechniquesFOXP3Peripheral tolerancehemic and immune systemsDendritic CellsBiological SciencesFlow CytometryAcquired immune systemTamoxifenImmunologybiology.proteinCD8T-Lymphocytes CytotoxicProceedings of the National Academy of Sciences
researchProduct

Endometrial Adenocarcinoma in Syrian Hamsters Treated with Diethylstilbestrol, Tamoxifen and N-Ethyl-Nitrosourea

2006

The synthetic estrogen diethylstilbestrol (DES) causes marked abnormalities in the female hamster genital tract, after either prenatal or postnatal exposure, leading to endometrial hyperplasia and carcinoma. Acting as an initiating event, DES altering uterine development may facilitate the abnormal response of promoting agents. Tamoxifen (TAM) is an antiestrogen that competes for central and peripheral estrogen receptor (ERα). TAM exerts agonistic effects on E-dependent endometrial proliferation. N-ethyl-N-nitrosourea (ENU), a potent mutagenic agent, induces tumors in a variety of organs, predominantly in the peripheral nervous system. To test whether ENU and TAM treatment in a model of hyp…

business.industryDiethylstilbestrolEstrogen receptorHamsterAntiestrogenHyperestrogenismmedicine.diseaseEndometriumEndometrial hyperplasiamedicine.anatomical_structuremedicineCancer researchmedicine.symptomskin and connective tissue diseasesbusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drug
researchProduct

Steroid Receptor Expression in Endometria from Women Treated with Tamoxifen

1998

Abstract Breast cancer patients receiving tamoxifen (Tam) are at an increased risk for developing endometrial carcinomas, possibly due to the partial estrogenic effect of Tam on endometrial cells. Progestational therapy has not routinely been included in Tam regimens. It was our aim to determine the presence of estrogen receptors (ERs) and progesterone receptors (PRs) in normal and abnormal endometria from postmenopausal women with breast cancer who were treated with Tam. Standard immunohistochemical staining of ERs and PRs was performed on paraffin sections from formalin-fixed uterine curettings or hysterectomy specimens from 40 patients who had received 20–40 mg of Tam daily for a minimum…

medicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classReceptor expressionEstrogen receptorBreast NeoplasmsEndometriumEndometriumBreast cancerInternal medicineEndometrial PolypHumansMedicineRetrospective Studiesbusiness.industryObstetrics and Gynecologymedicine.diseasePostmenopauseTamoxifenmedicine.anatomical_structureEndocrinologyReceptors EstrogenOncologyEstrogenAdenocarcinomaFemaleReceptors ProgesteronebusinessTamoxifenmedicine.drugGynecologic Oncology
researchProduct

Behandlung der ausgeprägten Pubertätsgynäkomastie mit Tamoxifen

1987

Based on the good results of another author 10 boys with marked pubertal gynecomastia were treated with the antioestrogen Tamoxifen (Nolvadex) at a dose of 20-40 mg/d orally for 2-12 months. In most cases the gynecomastia decreased totally, only two patients experienced palpable subareolar glandular tissue at the end of therapy. Side effects were not noted. During therapy levels of estradiol and testosteron increased, with a more pronounced elevation of estradiol. Basal values of LH and FSH remained nearly unchanged, but LH showed an increased response to LH-RH, which could be explained by the antioestrogenic effect of Tamoxifen at the hypothalamic level. The reduction of breast size in spi…

medicine.medical_specialtyChemotherapyEnd of therapybusiness.industrymedicine.medical_treatmentTherapeutic effectEstrogen receptormedicine.diseaseBlockadeBasal (phylogenetics)EndocrinologyGynecomastiaInternal medicinePediatrics Perinatology and Child Healthmedicineskin and connective tissue diseasesbusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugKlinische Pädiatrie
researchProduct

Tamoxifen, a Trigger Factor of Hereditary Angioedema with Normal C1-INH with a Specific Mutation in the F12 Gene (HAE-FXII)

2016

medicine.medical_specialtyTrigger factorSpecific mutationbusiness.industryImmunologymedicine.diseaseEndocrinologyInternal medicineHereditary angioedemamedicineCancer researchImmunology and AllergybusinessGeneTamoxifenmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Pure anti-oestrogens

2000

Pure anti-oestrogens are a group of at least five new compounds which are able to antagonize the effects of oestrogen in all tissues and species studied. The mechanism by which the pure anti-oestrogens produce their effects remains in question, but all of them are competitive antagonists of the oestrogen receptors and, moreover, have been proposed to block the shuttling of oestrogen receptors into the cell nucleus. When studied in vitro, these compounds are able to block the oestrogen-stimulated growth of breast cancer cells. In animals, their ability to block the effects of oestrogen on breast, uterus, bone, cardiovascular system and other reproductive-associated tissues has been demonstra…

medicine.medical_specialtyUterusBreast NeoplasmsBreast cancerInternal medicineAnimalsHumansMedicineIn patientskin and connective tissue diseasesReceptorFulvestrantEstradiolMolecular Structurebusiness.industryEstrogen AntagonistsObstetrics and Gynecologymedicine.diseaseIn vitroClinical trialEndocrinologymedicine.anatomical_structureReproductive MedicineCancer researchFemaleBreast cancer cellsbusinessTamoxifenmedicine.drugHuman Reproduction Update
researchProduct

The early response of the postmenopausal endometrium to tamoxifen: expression of estrogen receptors, progesterone receptors, and Ki-67 antigen

2003

OBJECTIVE To enlighten the early response of endometrium to tamoxifen by assessing the expression of estrogen receptors, progesterone receptors, Ki-67, and the histological response in endometria from normal postmenopausal women treated for 21 days with tamoxifen. DESIGN A total of 40 women, scheduled to undergo vaginal hysterectomy because of uterine prolapse, were randomly assigned to the tamoxifen group (20 mg/day; 20 women) or the control group (20 women). Samples were obtained from the upper and the lower thirds of the uterine cavity. Standard immunohistochemical staining of estrogen and progesterone receptors and of Ki-67 was performed on frozen sections. Staining was assessed using s…

medicine.medical_specialtymedicine.drug_classAdministration OralEstrogen receptorEndometriumEndometriumInternal medicineProgesterone receptormedicineHumansEstrogen receptor betabusiness.industryAntibodies MonoclonalObstetrics and GynecologyMiddle AgedImmunohistochemistryPostmenopauseTamoxifenKi-67 AntigenEndocrinologymedicine.anatomical_structureReceptors EstrogenEstrogenFemaleSimple Endometrial HyperplasiaReceptors ProgesteronebusinessEstrogen receptor alphahormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugMenopause
researchProduct

Three-dimensional hysterosonography for the study of endometrial tumors: comparison with conventional transvaginal sonography, hysterosalpingography,…

1997

We studied endometrial thickness and homogeneity in 36 patients with postmenopausal bleeding using three-dimensional ultrasound following distention of the uterine cavity with a sterile saline solution (3D-SHSG). Results with 3D-SHSG were compared with findings using transvaginal sonography, transvaginal sonohysterography, transvaginal color Doppler, and hysteroscopy. Sixteen patients (including three on tamoxifen) were undergoing hormone therapy at the time when they were studied. Visualization of the uterine cavity and of endometrial thickness was better with 3D-SHSG than with any of the other ultrasound techniques. The results with 3D-SHSG corresponded to the findings observed with hyste…

medicine.medical_specialtymedicine.medical_treatmentHysteroscopyEndometriumPolypsmedicineHumansHysterosalpingographyHysterosonographyUltrasonographymedicine.diagnostic_testbusiness.industryUltrasoundObstetrics and GynecologyHysterosalpingographyEndometrial NeoplasmsPostmenopausemedicine.anatomical_structureOncologyHysteroscopyEndometrial HyperplasiaFemaleUterine cavityHormone therapyRadiologybusinessTamoxifenmedicine.drugGynecologic oncology
researchProduct

Tubular carcinoma of the breast: Outcome and loco-regional recurrence in 307 patients

2005

Abstract Purpose The aim of this study is to describe the University of Florence experience in evaluating clinical, pathologic and treatment factors as they are related to the outcome and loco-regional recurrence in patients with tubular breast carcinoma. Material and methods Three hundred and seven patients (median age 56.4 years, range 26–91 years) with histological verified tubular carcinoma of the breast were consecutively treated at University of Florence from 1976 to 2001. All patients were followed for a median of 8.4 years (range 3 months to 20 years). Thirty-seven women underwent mastectomy and 270 underwent breast conserving surgery. Positive axillary nodes were found in 15% of pa…

medicine.medical_treatmentDiseaseSegmentalMastectomy SegmentalBreast cancerDuctalBreast-conserving surgery80 and overBreastAdjuvantMastectomyAged 80 and overCarcinoma Ductal BreastTubular carcinomaGeneral MedicineMiddle AgedCombined Modality TherapyTreatment OutcomeBreast cancer; Radiotherapy; Tubular carcinoma; Adenocarcinoma; Adult; Aged; Aged 80 and over; Antineoplastic Agents Hormonal; Axilla; Breast Neoplasms; Carcinoma Ductal Breast; Chemotherapy Adjuvant; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy Segmental; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards Models; Radiotherapy Adjuvant; Survival Analysis; Tamoxifen; Treatment Outcome; Oncology; SurgeryLocalOncologyChemotherapy AdjuvantLymphatic MetastasisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic Agents HormonalAntineoplastic AgentsBreast NeoplasmsAdenocarcinomaBreast cancermedicineChemotherapyHumansAgedProportional Hazards ModelsChemotherapyRadiotherapyHormonalbusiness.industryCarcinomamedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTamoxifenNeoplasm RecurrenceAxillaRadiotherapy AdjuvantSurgeryTubular carcinomaNeoplasm Recurrence LocalbusinessTamoxifen
researchProduct